Perilous Reversal Watch: ANI Pharmaceuticals (ANIP)
Trade-Ideas LLC identified
(
) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified ANI Pharmaceuticals as such a stock due to the following factors:
- ANIP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $17.0 million.
- ANIP has traded 52,027 shares today.
- ANIP is down 4.6% today.
- ANIP was up 6.1% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ANIP with the Ticky from Trade-Ideas. See the FREE profile for ANIP NOW at Trade-Ideas
More details on ANIP:
ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. It manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products. ANIP has a PE ratio of 14. Currently there are 2 analysts that rate ANI Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for ANI Pharmaceuticals has been 407,900 shares per day over the past 30 days. ANI has a market cap of $463.4 million and is part of the health care sector and drugs industry. The stock has a beta of 3.16 and a short float of 24.5% with 4.62 days to cover. Shares are down 24.1% year-to-date as of the close of trading on Friday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates ANI Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and a generally disappointing performance in the stock itself.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 3.7%. Since the same quarter one year prior, revenues rose by 14.9%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- Net operating cash flow has significantly increased by 147.03% to $10.27 million when compared to the same quarter last year. In addition, ANI PHARMACEUTICALS INC has also vastly surpassed the industry average cash flow growth rate of -0.70%.
- ANI PHARMACEUTICALS INC's earnings per share declined by 33.9% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ANI PHARMACEUTICALS INC turned its bottom line around by earning $2.53 versus -$5.54 in the prior year. This year, the market expects an improvement in earnings ($2.70 versus $2.53).
- The share price of ANI PHARMACEUTICALS INC has not done very well: it is down 23.48% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
- The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Pharmaceuticals industry average. The net income has significantly decreased by 32.4% when compared to the same quarter one year ago, falling from $6.75 million to $4.56 million.
- You can view the full ANI Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.